

## COVID, Kidney, Disease & SARS-CoV-2

Tobias B. Huber

Chair III. Department of Medicine

Nephrology, Transplantation, Rheumatology, Endocrinology

**UKE-Hamburg** 

The Coronavirus Outbreak >



LIVE Latest Updates Maps and Tracker States Reopening Living at Home

## An Overlooked, Possibly Fatal Coronavirus Crisis: A Dire Need for Kidney Dialysis

Ventilators aren't the only machines in intensive care units that are in short supply. Doctors have been confronting an unexpected rise in patients with failing kidneys.



## CKD & COVID-19


## Italy (Brescia)


- 643 dialysis patients
- 94 (15%) SARS-CoV-2 positive
- 57 (61%) required hospitalization
- Mortality 29%

## High risk of severe Covid-19 in patients with Chronic Kidney Disease

 All patients on maintenance hemodialysis in Wuhan, China (n = 7154)

Incidence of Covid-19 ~2.2%






Xiong et al. J Am Soc Nephrol 2020

Trujillo et al. Kidney Int Rep 2020


## **COVID-19 in Germany**

Up to June 2, 2020

- 182'028 cases
   (2'775 cases in the last 7 days)
- 8'522 deaths




Cumulative incidence per 100`000 persons





## COVID-19 Registry of the German Society of Nephrology

Data available for approx. 14'000 dialysis patients




E. Hoxha, JE Turner, TB Huber, UKE

## Patients with kidney disease are particularly vulnerable to COVID-19

- Older age, common comorbidities, increased mortality risk
- Impairment of immune system (because of ESKD, the underlying disease or its treatment)
- No home-isolation possible (esp. in-center dialysis patients)

## AKI & COVID-19

## Renal involvement in Covid-19 patients is frequent and predicts mortality



#### ACUTE KIDNEY INJURY IN PATIENTS HOSPITALIZED WITH COVID-19

Jamie S. Hirsch, Jia H. Ng, Daniel W. Ross, Purva Sharma, Hitesh H. Shah, Richard L. Barnett, Azzour D. Hazzan, Steven Fishbane, Kenar D. Jhaveri, on behalf of the Northwell COVID-19 Research Consortium and the Northwell Nephrology COVID-19 Research Consortium


## Acute kidney injury in COVID-19 patients

	No use of invasive mechanical ventilation (N=4259)	Required invasive mechanical ventilation (N=1190)
No AKI	3334 (78.3%)	122 (10.3%)
AKI, any stage	925 (21.7%)	1068 (89.7%)
AKI stage 1	639 (15.0%)	288 (24.2%)
AKI stage 2	185 (4.3%)	262 (22.0%)
AKI stage 3	101 (2.4%)	518 (43.5%)
Required renal replacement therapy	9 (0.2%)	276 (23.2%)

## **Akute Kidney Injury in Covid-19 patients**

Metaanalysis of 9 studies (mostly China) with ~2800 patients.


JASN study not yet included



Arentz et al. JAMA 2020; Cheng et al. Kidney Int. 2020; Guan et al. N Engl J Med. 2020; Huang Lancet 2020; Shi et al. JAMA Cardiol 2020; Wang et al. Am J Nephrol 2020; Wang et al. JAMA 2020; Yang et al. Lancet Respir Med 2020; Zhou et al. Lancet 2020.

## Renal involvement in Covid-19 patients is frequent and predicts mortality

333 hospitalized patients with Covid-19 pneumonia, single center, China



## Acute kidney injury in COVID-19 patients

- Acute tubule injury
- Endothelial damage
- Secondary damage
   (drug-induced, ischemic injury, secondary infections, rhabdomyolysis, etc.)
- Virulence of SARS-CoV-2 in the kidney?
   (tubular epithelium, podocytes, other glomerular cells)


## SARS-CoV-2 & Kidney



The NEW ENGLAND JOURNAL of MEDICINE

#### CORRESPONDENCE

#### Multiorgan and Renal Tropism of SARS-CoV-2



Teams Microbiology, Legal Medicine, Nephrology

Victor G. Puelles, M.D., Ph.D. Marc Lütgehetmann, M.D. Maja T. Lindenmeyer, Ph.D. Jan P. Sperhake, M.D.

#### Milagros N. Wong, M.D.

Lena Allweiss, Ph.D.
Silvia Chilla
Axel Heinemann, M.D.
Nicola Wanner, Ph.D.
Shuya Liu, Ph.D.
Fabian Braun, M.D.
Shun Lu, Ph.D.
Susanne Pfefferle, M.D.
Ann S. Schröder, M.D.
Carolin Edler, M.D.

University Medical Center Hamburg-Eppendorf Hamburg, Germany

Oliver Gross, M.D. University Medical Center Göttingen Göttingen, Germany

Markus Glatzel, M.D. Dominic Wichmann, M.D. Thorsten Wiech, M.D. Stefan Kluge, M.D.

Klaus Pueschel, M.D. Martin Aepfelbacher, M.D. Tobias B. Huber, M.D.

University Medical Center Hamburg-Eppendorf Hamburg, Germany t.huber@uke.de




<u>Table S1.</u> This table summarizes post-mortem interval (PMI), number of coexisting conditions highlighting affected organ systems including chronic kidney disease (kidney), and laboratory findings, including urinary analysis, blood urea nitrogen (BUN), estimated glomerular filtration rate (eGFR) and SARS-CoV-2 RNA copies per kidney cell.

Identifiers Number of coexisting conditions							Laboratory findings				
ase	(dake)	Respiratory bact	Cardibvascular system	ludney	Brain	Metabolism	Other	Urine analysis	BUN (mmol/l)	eGFK (ml/min/1,73m²)	Kidne PCR
1	1	- 2		10-	-	1	8	NA	NA	NA NA	<dt< td=""></dt<>
2	1		2	1	1		-	NA	16,84	20	0,0902
3	2	1	1	100	-		1	NA	3,50	52,4	<dt< td=""></dt<>
4	1	1	-	-	-	2	-	NA NA	2,67	92,3	0,0391
5	2		1	100			1-1	NA	NA	NA NA	<dt< td=""></dt<>
6	1		-		2		1	NA	NA	88,9	0,3219
7	4	-	2		-	-	1	Protein (+), Erythrocytes (++)	NA	55,1	0,0899
8	1	-	1	100	1	1	-	NA	NA	50,8	0,0122
9	4	1	1	1			1	NA	NA	36,9	18,693
10	5	-	1	1	-	1	-	NA	NA	36,2	1,214
11	2	1	3	100			1	Normal	4,34	60,9	0,0078
12	3			1 16		1		NA	3,00	85,1	NA
13	3	1	1	-	-	-	-21	NA	NA	53,0	0,9050
14	2		2		1	1	-	NA NA	NA	NA	0,001
15	2		2				100	NA	NA	NA NA	<dt< td=""></dt<>
16	1	1	1		1	-	-	NA NA	NA	NA	0,0050
17	2	1	1	1	2		10-01	NA	NA	NA NA	0,052
18	2	1	3		-	1	-	NA	13,84	36,0	0,0066
19	2	1	3	1		-	-	NA	10,51	28,0	<dt< td=""></dt<>
20	6	1	1		1		1	NA	NA	NA	<dt< td=""></dt<>
21	0	-	3	1	-	-	1	Protein (+)	17,18	14,0	<dt< td=""></dt<>
22	4	1	3	1			-	NA	26,02	26,0	<dt< td=""></dt<>
23	2				1		2	NA	10,34	82,0	0,0101
24	NA		3	1	-		-	NA	NA	NA NA	<dt< td=""></dt<>
25	3		2	1		1	11.0	NA	19,01	85	0,3395
26	9		2	1 -	1	+-	+	NA NA	9,67	40,0	0,137
27	9		3	1		1	-	NA .	13,17	20,0	<dt< td=""></dt<>

In number of coexisting conditions (-) represents absence in the clinical records; NA: not available;  $^{\sharp}$ obtained with urinary stix and sediment,  $^{\$}$ patient was on dialysis since 2014,  $^{\$}$ total SARS-CoV-2 RNA copies corrected for beta  $\beta$ -globin, <DT: below detection threshold.

Patients dying from COVID-19 have a high number of co-morbidities





Higher number of co-morbidities associates with multiorgan tropism



	Heart PCR		Liver PCR		Brain PCR		Kidney PCR	
If of coexisting conditions	(-)	(+)	(-)	(+)	(-)	(+)	(-)	(+)
1-2	1 (20%)	4 (80%)	1 (20%)	4 (80%)	1 (25%)	3 (75%)	3 (75%)	1 (25%)
3-5	4 (24%)	13 (76%)	4 (24%)	13 (76%)	12 (71%)	5 (29%)	5 (29%)	12 (71%)


Particularly, kidney tropism increases with co-morbidities



<u>Table S3.</u> This table summarizes renal tropism of SARS-CoV-2 [Kidney PCR (+)] in the presence or absence of reported chronic kidney disease (CKD).

		Kidney PCR		
OKD history	W of cases	(-)	(+)	
With history of CKD	8	4 (50%)	4 (50%)	
Without history of CKD	10	1 (10%)	9 (90%)	


In patients with preexisting CKD, there seems to be less kidney tropism



After the respiratory tract, kidneys exhibits the highes viral load




Fig. S1. SARS-CoV-2 infection adhesion and facilitator genes in renal cells



The high presence of SARS-CoV-2 infection adhesion and facilitator genes throughout different kidney compartments is shown using an in-silico analysis of publicly available single cell RNA sequencing data. Data was retrieved from Muus et al.<sup>6</sup> and Hochane et al.<sup>7</sup>.


Kidneys do express SARS-CoV-2 adhesion and facilitator genes






ISH detects SARS-CoV-2 RNA in the kidney






IF confirms SARS-CoV-2 protein in the kidney














Panel A shows that SARS-CoV-2 is detected in random kidney samples containing both cortex and medulla and Panel B shows SARS-CoV-2 detection in all renal compartments, especially in kidney glomeruli; where TI represents the tubulo-interstitial compartment.


Enrichement of SARS-CoV-2 in the glomerular compartment



# SARS-CoV-2 & Kidney Outlook



## Can urine abnormalities serve as outcome predictors in COVID-19 patients?



Gross O, Moerer O, Weber M, Huber TB, Scheithauer S, Lancet, May 16, 395, 2020

